Genetic Technologies Limited www.genetype.com info@gtglabs.com ABN 17 009 212 328 60 - 66 Hanover Street Fitzroy Victoria 3065 Australia +61 3 8412 7000 Melbourne, Australia, 24 November 2021: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, announces the following: In accordance with ASX Listing Rule 3.13.2 & section 251AA of the Corporations Act, the following information is provided to the ASX in relation to the resolutions passed by the shareholders of the Company, at its Annual General Meeting of shareholders held on 24 November, 2021. All resolutions put to the meeting were passed on a poll, called by the Chairman pursuant to the Notice of Meeting. A summary of the Poll voting results is set out on the following page. Authorised by: Mike Tonroe Company Secretary On behalf of the Board of Directors Genetic Technologies Limited +61 3 8412 7000 Investor Relations (AUS) Investor Relations and Media (US) Stephanie Ottens Dave Gentry Market Eye 1 800 RED CHIP (733 2447) M: +61 434 405 400 Cell: 407 491 4498 E: stephanie.ottens@marketeye.com.au E: dave@redchip.com About Genetic Technologies Limited Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. For more information, please visit www.genetype.com Results of Annual General Meeting The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2. Resolution Result If s250U applies Resolution Resolution Type For Against Proxy's Discretion Abstain For Against Abstain* Carried / Not Carried 518,957,497 98,198,665 82,282,672 242,585,128 603,914,770 98,198,665 242,585,128 74.20% 14.04% 11.76% 86.01% 13.99% 945,175,413 302,407,169 109,139,815 22,273,427 1,056,989,829 302,407,169 22,273,427 69.66% 22.29% 8.05% 77.75% 22.25% 1,035,079,989 223,794,596 105,450,704 14,671,135 1,143,205,294 223,794,596 14,671,135 75.87% 16.40% 7.73% 83.63% 16.37% 1,033,906,035 215,762,182 105,362,672 23,964,935 1,141,943,308 215,762,182 23,964,935 76.30% 15.92% 7.78% 84.11% 15.89% 1,025,496,635 223,876,982 105,647,672 23,974,535 1,133,818,908 223,876,982 23,974,535 75.68% 16.52% 7.80% 83.51% 16.49% 720,201,862 116,797,050 105,389,815 23,805,235 805,766,278 116,797,050 23,805,235 76.43% 12.39% 11.18% 87.34% 12.66% 960,067,508 280,100,666 105,389,815 33,438,435 1,068,131,924 280,100,666 33,438,435 71.35% 20.82% 7.83% 79.22% 20.78% * Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. Genetic Technologies Limited 2021 Annual General Meeting Wednesday, 24 November 2021 Results of Meeting Resolution details Instructions given to validly appointed proxies (as at proxy close) Number of votes cast on the poll (where applicable) 1 Adoption of the Remuneration Report Ordinary Carried 2 Re-Election of Dr Jerzy (George) Muchnicki Ordinary Carried 3 Approval of proposed issue of Warrants Ordinary Carried 4 Prior issue of Shares under ASX Listing Rule 7.1 Ordinary Carried 7 Approval of Increased Placement Capacity Special Carried 5 Prior issue of Shares under ASX Listing Rule 7.1A Ordinary Carried 6 Adoption of Employee Share and Option Plan Ordinary Carried
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Genetic Technologies Limited (ASX:GTG) when you join Listcorp.